INTRODUCTION
Few areas of scientific investigation have been as controversial as that of the role of Ureaplasma urealyticum in human disease, particularly as it relates to pregnancy outcome (11) . Over the years, ureaplasmas have been implicated in infertility, spontaneous abortion, stillbirth, premature birth, low birth weight, and perinatal morbidity and mortality (11) . While it is now clear that ureaplasmal colonization of the lower genital tract is not associated with adverse pregnancy outcome (9, 11) , ureaplasmal infection of the chorioamnion is strongly associated with chorioamnionitis (14, 17, 33, 52, 62, 94, 95) , premature birth (15, 52, 62) , and perinatal morbidity and mortality (14, 33, 62, 94, 95) . Case reports indicate that the infection is causal in at least some individuals (14, 16, 38, 96) .
Recent evidence indicates that U. urealyticum is the single most common microorganism isolated from the central nervous system (CNS) (147, 149) and lower respiratory tract (16) of newborn infants, particularly those born prematurely. Isolation of the organism in pure culture from pleural fluid (5, 16, 146, 152) , lung biopsy samples (152) , and lung tissue at autopsy (5, 16, 146) from infants with pneumonia and repro-* Corresponding author. duction of similar histologic lesions in lungs of newborn mice (112) and nonhuman primates (151) with these isolates (112) prove that this organism is a cause of respiratory disease in newborns. Prospective studies from six different centers (16, 91, 113, 154, 159, 161) now indicate a significant association between U. urealyticum in the lower respiratory tract and development of chronic lung disease (CLD) in low-birthweight infants. While the occurrence of clinically significant hydrocephalus and meningitis is variable in ureaplasmal CNS infections, it is clear that in some cases it is causal (42, 147, 149) . Available evidence indicates that U. urealyticuminduced CNS and respiratory diseases are uncommon in full-term infants (13, 67, 68, 74, 132, 147, 149) .
A major need for future research is the identification of risk factors for chorioamnion infection and risk factor for increased susceptibility of premature infants to ureaplasmal disease in premature infants. Current evidence suggests but does not prove that lack of specific antibody may be a critical determinant. There is limited information concerning guidelines or efficacy of antibiotic therapy of ureaplasmal infections, particularly in neonates. Because of the frequency of these infections and their potential severity in some neonates, there is a critical need for work in the area of therapy.
The present review is not meant to be inclusive; rather, its purposes are to (i) give some insight into why there has been so much controversy concerning the role of U. urealyticum in adverse pregnancy outcome; (ii) summarize evidence establishing ureaplasmas as a cause of intrauterine infection and premature birth; (iii) summarize evidence of a role for U. urealyticum in disease of very low-birth-weight infants; and (iv) discuss considerations for laboratory diagnosis and therapy. Emphasis will be placed on remaining questions and those areas of greatest need for further study.
EXPLANATION OF PREVIOUS CONTROVERSY
Most studies that have addressed the role of U. urealyticum in adverse pregnancy outcome have used one of three approaches: comparative rates of isolation from the lower genital tract, comparative rates of isolation from placentas or infants, or outcome of pregnancy following antibiotic therapy. As is often true of clinical studies with any organism, most studies of U. urealyticum have suffered from one or more of the following defects: (i) failure to appropriately exclude possible involvement of other infectious agents; (ii) failure to include placebo controls; (iii) inadequate numbers of patients and controls so that statistical reliability is never achieved; (iv) failure to match the groups for factors known to influence ureaplasmal colonization (i.e., race, socioeconomic status with regard to cervical colonization, and duration of membrane rupture and labor with regard to chorioamnion or amniotic fluid infection); (v) inadequate diagnostic evaluations of patients so as to exclude obstetric and gynecologic factors that can confound an association with U. urealyticum; and (vi) limitation of the investigation to epidemiological studies, which by themselves can suggest a relationship between ureaplasmas and disease but can never prove a cause-and-effect relationship. Furthermore, adverse outcome of pregnancy has many causes. Failure to incorporate this concept into experimental designs coupled with the high prevalence of the organism almost guarantees negative results. Only in very few studies has the probability that ureaplasmas are likely to be related to adverse outcome only in certain clinicopathologic subsets been considered.
As already mentioned, it is now clear that U. urealyticum cervicovaginal colonization is not predictive of adverse pregnancy outcome (9, 11) . However, it is also clear that U. urealyticum can invade the upper genital tract and does so only in a subpopulation of individuals infected with ureaplasmas in the lower genital tract (14, 20) . Herein lies the root of most of the controversy. Most of the earlier studies were limited to culture of the cervix and/or vagina or to surface cultures of infants.
Most available information indicates that if any organism causes adverse pregnancy outcome it most likely does so by infection of the chorioamnion and/or amniotic fluid and fetus. Thus, simply comparing rates of isolation from the lower genital tracts of different patient populations is not likely to establish whether there is an etiologic significance for U. urealyticum or, for that matter, any other microorganism in pregnancy-related conditions. In fact, relying on culture of the cervix and vagina would be much like attempting to determine the etiologic agent(s) of pneumonia by culturing the oro-or nasopharynx (9) . Harrison and Phil eloquently stated (51) the fallacy of such an attempt: "Assume that 10% of U. urealyticum infected women are at risk for invasion and abnormal pregnancy outcome and that this 10% cannot be identified a priori. Then the other 90% would carry the same risk of abnormal outcome as uninfected women. Assume also that the prevalence of ureaplasmal endocervical infection in pregnancy is about 75% and that the overall incidence in the population of the outcome to be investigated is about 5%. Using U. urealyticum endocervical infection as the risk factor, the minimum relative risk for the adverse outcome that could be detected is a p = 0.05 and power of 0.80 is 2.1. For the overall risk in colonized women to be 2.1, the relative risk in the unknown 10% subgroup at risk must be 12.0. This would require 60% (12 x .05) of this subgroup to have the abnormal outcome. It is unlikely, given the multitude of other anatomic, physiologic and microbiologic factors that are probably important in addition to host susceptibility, that the 60% level of abnormal outcome in the subgroup at risk ever occurs."
In contrast to studies limited to isolation of U. urealyticum from the lower genital tract or surface cultures of the infant, studies based on infection of the placenta indicate a strong association between isolation of U. urealyticum from the placenta and histologic chorioamnionitis (17, 33, 52, 62, 94, 95) , premature birth (15, 33, 52, 62) , and perinatal morbidity and mortality (14, 16, 38, 96) . While most of the earlier studies either did not evaluate the contribution of other microorganisms or did not take into account membrane rupture, duration of labor, or other demographic and obstetric confounding variables, results of more recent studies (15, 52) that have taken these factors into account still show a strong association of U. urealyticum infection of the chorioamnion with chorioamnionitis and prematurity. Individual case reports provide compelling evidence that, in at least some individuals, U. urealyticum alone plays a causal role in spontaneous abortion (38) , chorioamnionitis (14, 17, 38) , and premature birth (15) . Recent prospective and experimental studies also indicate that U. urealyticum is a significant cause of morbidity and mortality in newborns, particularly those of low birth weight (13, 16, 144) .
COLONIZATION OF THE LOWER GENITAL TRACT
AND EPIDEMIOLOGICAL CONSIDERATIONS U. urealyticum can be found in the cervix or vagina of 40 to 80% of sexually mature asymptomatic women (12, 18, 77, 78, 80) . Colonization is linked to younger age, lower socioeconomic status, sexual activity with multiple partners, black ethnicity, and oral contraceptive use (77, 78, 80) . Vertical transmission of U. urealyticum occurs at rates of 45 to 66% in full-term infants (29, 114, 132) and 58% in preterm infants (115) .
Isolation of U. urealyticum in pure culture from placenta, amniotic fluid, and internal fetal organs in the presence of funisitis and pneumonia (14) and a specific immunoglobulin M (IgM) response (96) can be taken as strong evidence that fetal infection can occur in utero. Cassell et al. (16) found that up to 14% of U. urealyticum endotracheal isolates collected within the first 12 to 24 h after birth from infants whose birth weight was less than 2,500 g were from infants born by cesarean section with intact membranes, indicating that in utero transmission occurs rather commonly, at least in premature infants. However, the precise rate of in utero transmission and its impact on perinatal morbidity and mortality have not been determined. Nosocomial transmission of mycoplasmas in a newborn or intensive care nursery has not been reported, and whether it occurs is not known.
Colonization of healthy full-term infants is relatively transient, with a sharp drop in isolation rates after 3 months of age (39, 60) . Long-term follow-up studies with premature infants have not been conducted. In premature infants with invasive ureaplasmal infection, persistence of the organism in the lower respiratory tract (16) (17) . These findings provide a convincing argument that ureaplasmas alone can actually produce chorioamnionitis. The presence of funisitis in such cases provides strong evidence that fetal infection can occur in utero (14, 16) .
Studies based on isolation of U. urealyticum from the placenta have uniformly shown a significant association with chorioamnionitis (17, 33, 52, 62, 94, 95) . While some studies did not rigorously seek other infectious agents and did not take into account duration of labor and/or membrane rupture, recent studies in which all possible agents were sought showed that women whose amniotic membranes were colonized with ureaplasmas were more likely to have chorioamnionitis than were women without U. urealyticum, even after rates were adjusted for duration of labor, premature rupture of membranes, duration of membrane rupture, and presence of other bacteria (52) . In recent studies conducted in our laboratory, U. urealyticum in the chorioamnion was found to be significantly associated with chorioamnionitis, even in the presence of intact membranes in women who delivered by cesarean section (15) . In some of these placentas ureaplasmas were the only organism isolated. Thus, there is ample evidence that U. urealyticum in the placenta is significantly associated with chorioamnionitis. Although colonization of the endometrium prior to conception could undoubtedly result in infection of the amniotic sac, either an ascending or a hematogenous route of infection could also occur during pregnancy. U. urealyticum has been isolated from maternal blood in cases of septic abortion (38) , but it appears that most infections probably occur via the ascending route and generally remain clinically silent. Unlike most other bacterial infections, ureaplasmal infection of the amniotic fluid is not associated with fever and uterine tenderness, and thus it is not a significant cause of clinical amnionitis (17) .
CHORIOAMNION INFECTION AND PERINATAL

MORBIDITY AND MORTALITY
When considering the potential adverse effect of U. urealyticum infection on pregnancy, it is important to consider the following facts. As already discussed, ureaplasmas can cause a clinically silent infection of the endometrium and can invade the amniotic sac as early as 12 to 16 weeks of gestation, even in the presence of a viable, apparently healthy fetus and intact fetal membranes (14, 38) .
U. urealyticum has been implicated in spontaneous abortion, in some cases in association with maternal septicemia (12, 38, 80) . The organisms have been isolated from fetal lungs, brains, hearts, and viscera (12, 14, 80, 94) . U. urealyticum has been isolated more frequently from the products of early abortions and midtrimester fetal losses than from products of induced abortions (123, 128) . Although rates of isolation of ureaplasmas from the lower genital tract of habitual aborters do not differ from those of normal controls, ureaplasmas are isolated more often from the endometria of habitual aborters (128) . However, when only those patients with a positive cervical culture are considered, no higher endometrial colonization rate is found (85) . U. urealyticum is isolated more frequently from the placentas of aborted fetuses than from those of controls (33, 94) .
Antibody titers to U. urealyticum are higher in mothers with a history of fetal wastage (99) . However, the results of all of these epidemiologic studies are difficult to interpret since the comparability of the various groups of women is uncertain and the role of other microorganisms was often not assessed. Some studies have indicated an increase in the number of normal pregnancies following treatment with broad-spectrum antibiotics or erythromycin (98) , but either these trials have been uncontrolled or the numbers of patients have been too few to achieve statistical reliability. However, isolation of U. urealyticum from amniotic fluid in pure culture from women with preterm labor and subsequent fetal loss in the presence of chorioamnionitis has recently been reported (14, 38) . Unlike previous reports, these data clearly show that the fetus was alive prior to ureaplasmal infection and that there were no other apparent causes of abortion. This indicates that, in some cases, the role of U. urealyticum is causal.
Chorioamnionitis AND PREMATURE BIRTH Preterm birth (gestation of <37 weeks; birth weight of <2,500 g) is the single most common risk factor for infant morbidity and mortality, affecting 8 to 10% of all births and contributing to more than 60% of all perinatal morbidity and mortality (53, 82) . Preterm infants are 40 times more likely to die in the neonatal period than are those with normal birth weights (53, 82) . Five million hospital days per year are required for the care of those preterm infants who survive (53, 82) . Neonatal intensive care costs exceed $5 billion.
A large body of evidence suggests that infection may play a major role in premature birth (43) (44) (45) 52) , and a significant proportion of that premature birth may therefore be preventable. The first suggestion that infection might be involved in prematurity and low birth weight resulted from studies in which tetracycline was administered to nonbacteriuric pregnant women on a double-blind basis (32) . Women who were treated for 6 weeks during pregnancy gave birth to significantly fewer infants weighing <2,500 g than women given a placebo. Although no microbiologic investigations were conducted, it was postulated that tetracycline-susceptible microorganisms might be responsible for low birth weight, and mycoplasmas were considered among such microorganisms. (34, 75, 76, 124) . A 1,000-fold increase in the concentration of anaerobic microorganisms and a 100-fold increase in the concentration of G. vaginalis have been documented (44, 124) . Although U. urealyticum is not independently associated with BV, the prevalence of vaginal colonization by U.
urealyticum is increased about 2-fold, and the intravaginal concentration of these organisms is increased 100-fold (44) . BV is associated with premature birth. However, the precise relationship among BV, U. urealyticum, and premature birth is not known. Some have postulated that the increased intravaginal concentrations of BV organisms may result in increases in the synthesis of phospholipase A2 and the production of prostaglandins, which may lead to preterm labor or premature rupture of membranes (34, 75) . Alternatively (34, 75) , Bacteroides spp. in the lower genital tract could produce enough proteases to weaken the fetal membrane strength, causing premature rupture of membranes and invasion by other organisms. In addition, it is possible that certain BV-associated microorganisms, such as U. urealyticum, may be more likely to invade the intact fetal membranes simply because these organisms are present in larger numbers. However, the latter possibility cannot be the total explanation for U. urealyticum association with prematurity, since intravaginal concentrations of Peptococcus spp. are also increased in patients with BV but are found infrequently in the chorioamnion and amniotic fluid (15, 34, 52, 75, 76, 124) .
The presence of BV is independently and significantly associated with birth at <37 weeks of gestation when cervical organisms and obstetric and demographic factors are taken into consideration (52 (3, 8, 45, 48, 66, 107, 143, 150) . Only a few of the studies urealyticum from the chorioamnion was inversely related to both gestational age and birth weight. In our study, almost 50% of the ureaplasmal chorioamnion isolates were in pure culture. Although M. hominis and G. vaginalis were the next most common organisms isolated, they, unlike U. urealyticum, were not independently associated with birth at <37 weeks of gestation. Thus, the relationship between BV and prematurity with or without U. urealyticum infection remains unclear. Current evidence indicates a distinct possibility that both BV and U. urealyticum are of etiologic significance independently of each other yet may have an additive effect when present simultaneously. In this regard, it is interesting that in our study the effect of U. urealyticum plus other bacteria was additive. U. urealyticum, like other bacteria implicated in prematurity, is known to produce phospholipase A2, a precursor of prostaglandin synthesis that is thought to lead to uterine contractions (26, 27) .
CONGENITAL AND NEONATAL PNEUMONIA Congenital pneumonia or pneumonia acquired during birth is almost always accompanied by chorioamnionitis (31, 86) .
Since it appears that U. urealyticum can cause chorioamnionitis, it is reasonable to suspect that this organism is also a cause of pneumonia in newborns. In fact, retrospective studies indicate an association of ureaplasmas with congenital pneumonia (133) . U. urealyticum has been isolated from affected lungs in the absence of bacteria, fungi, viruses, and chlamydiae and in the presence of chorioamnionitis and funisitis (14, 38) . It has also been demonstrated within fetal membranes by immunofluorescence (17) and in lung lesions by electron and immunofluorescence microscopy (96) . A specific IgM response has been demonstrated in individual patients with pneumonia, further documenting in utero infection (96) . U. urealyticum can induce ciliostasis and mucosal lesions in human fetal tracheal organ cultures (96) . Furthermore, ureaplasmas isolated from the lungs of human infants with congenital pneumonia produce pneumonia in newborn animals (24, 112, 151) .
We have previously described (146) a series of newborn infants in whom U. urealyticum was isolated from the lower respiratory tract and pneumonia and persistent pulmonary hypertension were present. A severely asphyxiated, 2,200-g male infant born after 33 weeks of gestation had multiple U. urealyticum-positive cultures from blood, pleural fluid, and tracheal aspirates in the absence of other microorganisms prior to his death on postnatal day 6. At autopsy, severe bilateral pneumonia with a mixed cellular intraalveolar inflammatory exudate and early fibrotic changes of bronchopulmonary dysplasia were confirmed. U. urealyticum was isolated in pure culture from nasopharynx, lung, and brain postmortem. The occurrence of histologically proven pneumonia in an infant from whom U. urealyticum was the only organism isolated from multiple sites before and after death, including the lungs at autopsy, proves unequivocally that this organism can produce pneumonia in a newborn infant (5, 146) .
The association of ureaplasmal infection with persistent pulmonary hypertension of the newborn is of particular interest in view of another study implicating group B streptococci with this condition and experimental studies in which streptococci have been shown to induce pulmonary hypertension when infused into the pulmonary circulation of animals (117) . A proposed mechanism relates to thromboxane formation as a result of arachidonic acid activity induced by phospholipases (135) . The production of phospholipases by ureaplasmas has been described elsewhere (26, 27) .
CLD AND DEATH OF THE NEWBORN
In addition to the acute respiratory distress commonly seen in preterm infants, the survival of a greater number of very low-birth-weight infants than ever before has led to the recognition of the clinical entity bronchopulmonary dysplasia, also known as CLD of prematurity. The pathophysiology and known risk factors for CLD have been reviewed in detail elsewhere (87) . Despite multiple intervention strategies, there has been little progress in reducing the mortality of CLD, which affects 15 to 38% of survivors of neonatal pulmonary disease with birth weights of < 1,500 g, since the first description of this condition over 20 years ago. This lack of progress has led to consideration of other pathologic mediators of the condition, one of which is U. urealyticum.
Four recent independent studies (16, 91, 113, 154) (13, 24, 91, 151) .
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Considering that there have been no prospective studies addressing the role of ureaplasmas in lower respiratory tract infections of infants outside the neonatal period that utilized direct cultures from the affected site (i.e., tracheal aspirates, lung biopsy samples, or autopsy material), no compelling evidence suggests that ureaplasmas are significant pathogens in lower respiratory tract infections in this population. Because of the well-documented difference in susceptibility of very low-birth-weight (i.e., extremely premature) infants versus older infants, we do not think that these organisms are likely to be a major cause of respiratory disease in otherwise healthy infants after the first month of life.
INFECTIONS OF THE CNS
The incidence of bacterial meningitis is greater in the neonatal period than in any other period in life (61), yet even in this select group epidemiological surveys place the attack rate at less than 1% (61) . The importance of bacterial invasion of the CNS and the need for its prompt investigation when suspected or when found are underscored because of the significant death rate and the incidence of neurologic handicaps in survivors. Only within the past decade has an appreciation of ureaplasmas as pathogens in the newborn gained sufficient acceptance that investigations of their role(s) as pathogens in the CNS are beginning to be undertaken.
We previously (149) studied 100 predominantly preterm infants undergoing lumbar puncture for suspected sepsis and/or meningitis or for treatment of posthemorrhagic hydrocephalus. Infants were derived from a high-risk, university-based obstetric population. U. urealyticum was isolated from eight infants and M. hominis was isolated from five infants. Only one other CSF infection, in an infant with Escherichia coli meningitis, was identified in this group of 100 infants, making ureaplasmas the most common organisms isolated. U. urealyticum was isolated from six infants with severe intraventricular hemorrhage and from three infants with hydrocephalus. U. urealyticum was isolated from the respiratory tracts of four of eight infants with CSF infections. One infant had clinical pneumonia with pleural effusions, from which the organism was also isolated. Four infants in whom multiple isolations of U. urealyticum were made over several weeks had each sustained an intraventricular hemorrhage at or shortly following birth and had large intraventricular blood clots, which may have sequestered organisms over long periods (149) . Four ureaplasma-infected infants died. The most striking features of M. hominisinduced CNS infection occurred in a full-term infant in whom the clinical features of congenital infection resembled those seen with viral or toxoplasmal infections and in whom major neurological impairment was noted.
A fundamental question that arose as a result of our former study (149) (144) . The recent production of meningitis and hydrocephalus in newborn mice and beagles by using pure cultures of U. urealyticum isolated from CSF of human infants (21a) indicates that these organisms do have the potential to produce CNS disease.
NEONATAL SEPSIS
The factor associated most significantly with sepsis due to any microorganism in the neonate is low birth weight (122) . Other factors include prolonged ruptured membranes, traumatic delivery, maternal infection, chorioamnionitis, and fetal hypoxia. In the case of U. urealyticum, as with any other bacterium, infection can occur at the time of birth when the infant is inoculated with the organism as it traverses the birth canal. Alternatively, the fetus may acquire the organism in utero through infected amniotic fluid or placenta. Placental infection with involvement of the umbilical vessels could lead to disseminated infection in the fetus, or aspiration of the organisms into the lungs could lead to pneumonitis and septicemia from a respiratory tract focus.
U. urealyticum has been isolated from cord blood (127 (129) . In fact, the investigators who suggested expanding the serotyping scheme to 14 have proposed deleting serovars 11 and 13 (126) . In serotyping clinical isolates, they found that repeated tests of serovar 11 showed poor agreement, while serovar 13 not only showed poor agreement but also occurred too frequently to aid in strain differentiation.
The percentages of clinical isolates typeable by using antisera to serovars 1 to 8, 1 to 10, or 1 to 14 are conflicting. It is disconcerting that up to 96% of isolates are typeable with antisera only to serovars 1 to 10 (84) and that up to 94% are typeable with antisera to serovars 1 to 8 (56) , while other studies using antisera to all 14 serovars found that serovars 11 through 14 can occur in 20 to 50% of patients (104) . These results may be explained by the tendency of clinical isolates to express multiple specificities (54, 84, 126, 157) . This is in part because of cross-reactivity alone but is also because of actual common expression of epitopes (54, 126, 157) . Admittedly, part of the problem may be lack of standardization of reagents and methods between laboratories.
Unfortunately, little is known concerning the nature of either type-specific or group-specific antigens. Preliminary data suggest that complement-fixing antigens are membrane lipids, whereas metabolism-inhibiting antibodies are directed mainly against membrane protein antigens (106). Typespecific antigens appear to be sensitive to mild protease and Triton X-114 treatment, which suggests that they may be surface-exposed proteins (126) .
Two studies involve analysis of U. urealyticum proteins by two-dimensional gel electrophoresis. One involved types 1 to 9, and the other involved types 1 to 9, 11, 12, and 14 (83, 131) . Although the serovars could be divided into the two genetic clusters (see below), only one serovar-unique protein was found and this was in serovar 9 (131) . All other polypeptides were common to all serovars, limited to one of the two genetic clusters, or found in two or more serovars which were not always of the same group. It appeared that about one-third of the polypeptides were common to all serovars and that most of the remainder were group specific. However, it is dangerous to draw conclusions concerning differences in antigenicity without the use of antibody, especially without the use of monospecific or monoclonal reagents. One study using immunoblotting reported detection of serogroup-specific antigens, but only 5 of the 14 serovars were evaluated with a limited number of sera (65) .
Previously (19, 54, 157) , we have shown that immunoblotting with rabbit antisera reveals an intensely staining, complex "ladder" pattern consisting of a series of proteins with molecular weight heterogeneity when some serovars, serovars 1, 2, 3, 5, and 6, are reacted with homologous antisera. The same ladder pattern also indicates a certain degree of relatedness between some members of the two biotypes of ureaplasmas (between serovars 2 and 5 and between serovars 3 and 14). Using monoclonal antibodies, we have demonstrated the occurrence of a ladder antigen also on serotypes 8 and 10 ( Fig. 1) . Thus, the ladder antigen has now been identified on 8 of the 14 serovars. Monoclonal antibodies to these ladder antigens have been produced. Detailed analysis of this antigen in serovars 3, 8, and 10 indicates that this antigen (i) is species specific; (ii) contains both serotypespecific and a cross-reactive epitope(s); (iii) is produced not only in vitro but also in vivo; (iv) undergoes a high rate of structural variation in vitro; (v) is present on invasive ureaplasma isolates, i.e., those from placenta, lung, and CSF; and (vi) is one of the most predominant protein antigens recognized during infections in humans (157) . Furthermore, we have shown that monoclonal antibodies to this antigen can inhibit the growth of these organisms in vitro, which suggests that antibody to this antigen may be impor- Serotyping of clinical isolates by any method is difficult at best. Growth inhibition or mycoplasmacidal assays require passage of primary isolates several times prior to serotyping (126) . As these methods are based on the growth of organisms, it is extremely difficult to detect the presence of all serovars in a mixture because certain serovars are more fastidious, grow more slowly, or can be present at lower concentrations (126) . Since mixed serovars can be cultured from 53% of patients (93) , this problem is a major concern. Immunofluorescence and immunoperoxidase methods allow typing directly on the primary isolation plate, but those who have examined these procedures systematically find that clinical isolates often express multiple specificities (54, 84, 126) . Lack of agreement between repeated assays following passage of isolates is also a problem (84, 126) . Given these limitations, it is not surprising that results linking specific U. urealyticum serovars with certain diseases are conflicting.
Eleven published articles deal with distribution of U. urealyticum serovars in different populations. In general, patient and control groups have been poorly characterized and the numbers in the groups have been small. In some instances, detection of serovar-specific antibody has been used in the absence of cultural isolation and documentation of the serovars present (97, 99) . Only one group of investigators has used antisera to all 14 serovars, and only one group has performed typing directly on the primary isolation plate (104, 126) . Five published reports examined the serovar distribution of U. urealyticum in patients with nongonococcal urethritis and in asymptomatic controls (23, 69, 92, 119, 126) . No serovar was consistently found to predominate. The remaining six reports deal with the distribution of serovars in various female and neonatal populations. Lin (69) used 11 typing sera and cervical isolates and determined the serovar distribution in normal college women, women with salpingitis, and pregnant women who delivered normal, low-birth-weight, or stillborn infants. There were no differences among the small groups examined. Naessens et al. (84) , using 10 typing sera, the first subculture of broth, and immunofluorescence, examined four groups of patients. Group 1 contained 24 couples with a history of recurrent abortion, group 2 contained 25 patients who had had their first spontaneous abortion, group 3 contained 14 pregnant patients with complications (premature delivery or intrauterine death), and group 4 contained 138 patients with uneventful pregnancies. They typed 240 strains (most were from cervices but some were from placentas and trophoblasts).
Serovar 4 was significantly more common in the cervices of group 1 patients (20.8%) than in those of control patients (5.1%).
Quinn et al. (99) , using the metabolic inhibition assay, measured antibody titers at delivery in 14 women with histories of pregnancy wastage (but who were treated with erythromycin) and in their infants and compared these with titers for 20 normal mothers and their infants. When the mean antibody titers in the normal and pregnancy wastage groups were calculated for serovars 1 to 8 (serovars 9 to 14 were not examined), the infants of mothers with pregnancy losses exhibited significantly elevated mean titers to serovars 6 and 8, while the mothers had elevated mean titers to serovars 4 and 8. A lack of significantly elevated antibody titers to serovar 3 has been used by these investigators to suggest that serovars 4 and 8 may be more pathogenic. In their population serovar 3 is found in 80% of all individuals. They have also suggested that the fact that serovar 8 produces more phospholipase A2 than serovars 4 and 3 may explain involvement of this serovar in premature birth (26, (25) .
Even though there are weaknesses in both studies, it is interesting that Quinn et al. (97, 99) (23, 119) and in the cervices of females with pelvic inflammatory disease (22) . Of eight serovars examined for their abilities to reduce the penetration of zona-free hamster eggs by human spermatozoa, serovar 4 was the only one to produce a significant effect (6 Additionally, this study showed that, even in isolates of the same serotype from different patients and in isolates from different body sites within the same patient, there can be size variation in the serotype antigens expressed (Fig. 1) . There- fore, it appears that many serotypes are invasive and that perhaps antigen variability and host factors may be more important determinants for ureaplasma infections than different serotypes per se.
ROLE OF ANTIBODY IN DEFENSE AGAINST UREAPLASMAS
Available evidence indicates that identification of specific antibody to U. urealyticum may be useful in detecting an active infectious process. Specific antibody to U. urealyticum can be detected by complement fixation, growth inhibition, metabolic inhibition, and mycoplasmacidal assays (121) . However, these methods are limited by technical difficulties and lack the ability to distinguish the responses among immunoglobulin classes. The latter capability may be of utmost importance in ultimately determining the etiologic significance of U. urealyticum. We have developed an enzyme-linked immunosorbent assay (ELISA) based on a whole organism lysate as the antigen (4). The assay agrees exceptionally well with results obtained by metabolic inhibition assay (overall agreements of 82 and 95% for acute-and convalescent-phase sera, respectively). Using this assay, we characterized the antibody response in a well-defined population of males with nongonococcal urethritis for whom quantitative cultural results were available over time. Serum antibody levels in nongonococcal urethritis patients were significantly higher than the normal serum standard for the IgG, IgM, and IgA classes. Additionally, the magnitude of change between acute-and convalescent-phase sera was greater for nongonococcal urethritis patients than for normal asymptomatic ureaplasma-positive male controls. A significant change in antibody levels of one or more antibody classes was detected by ELISA in 12 of 18 nongonococcal urethritis patients. Ten of the 12 individuals had a change in the IgM class, which suggests an active infectious process.
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We have used the ELISA to analyze sera from various female patient populations. Whereas the mere presence or absence of antibody, especially IgA, agrees well with cervicovaginal isolation of U. urealyticum (4), changes in antibody titer do not necessarily agree with cultural isolation of the organism from invasive sites (17) . This may be because our ELISA failed to detect serovar-specific antibody increases (54) . Two papers purport to demonstrate ureaplasma serovar-specific ELISAs (140, 160 ). Both assays were tested only with rabbit antisera, and both showed considerable cross-reactions which could be diluted out. However, careful examination of the data suggests that neither assay would prove clinically useful even if human serum reacted in the same fashion as rabbit antiserum. Considerable cross-reactions remained, despite serum dilutions of up to 1:1,000. Furthermore, a serovar-specific antibody response could not be demonstrated with sera from humans presumably exposed to only a single serovar (54) .
The unique susceptibility of hypogammaglobulinemic patients to chronic arthritis due to U. urealyticum (138) suggests that antibody is important for protection against invasive disease caused by this organism. Increased susceptibility of infants of <30 weeks of gestational age to U. urealyticuminduced respiratory disease may be related to their hypogammaglobulinemia (13, 16) .
Study of a hypogammaglobulinemic patient with arthritis provides evidence that serovar-specific antibody may be required for protection against invasive disease. A nonserovar-specific ELISA revealed high levels of ureaplasmaspecific antibodies in the serum of the patient as well as in two serum donors who served as sources of immunoglobulin replacement during the period of joint infection. However, by the serovar-specific metabolic inhibition assay, no antibodies to serovar 4, which was isolated from the joint and subcutaneous abscesses, were detected (142) . In another hypogammaglobulinemic patient with chronic arthritis due to an antibiotic-resistant strain of U. urealyticum, treatment with commercial immunoglobulin (Sandoz) was not effective but arthritis and abscesses resolved when the patient was given infusions of goat hyperimmune ureaplasma serum (138, 158) . Thus far, the serovars isolated from joints of hypogammaglobulinemic patients include 2, 4, 5, 7, and 8 and an untypeable strain. Generally, these are not the more common serovars isolated from the patient and control populations that have been surveyed. Perhaps commercial immunoglobulin preparations contain antibodies to the more common serovars such as 3 and 6.
That detection of serovar-specific U. urealyticum responses is clinically significant has also been suggested by Kass et al. (57) . They showed that women who experienced a fourfold or greater rise in antibody titer to any single strain of U. urealyticum had a 30% rate of low-birth-weight infants whereas women who did not experience such an increase in antibody titer had a 39% rate. Correspondingly, the birth weights in the two groups differed by 230 g. In most instances of significant increases in antibody titer, the titer increase was specific for a serologic type other than those for which the women had preexistent antibody and the typespecific titer increased from undetectable levels. The data reported by Quinn et al. (96, 97, Only half of those with ureaplasma-positive cultures of the chorioamnion will also have positive culture of the amniotic fluid (15) . The fact that analysis by the more sensitive technique of polymerase chain reaction also indicates a much lower frequency of infection in amniotic fluid than in the chorioamnion confirms that reliance on analysis of amniotic fluid will lead to underdiagnosis of chorioamnion infection and hence chorioamnionitis (15 (10, 18, 120, 121, 145, 148) 6, 1993 on November 6, 2017 by guest http://cmr.asm.org/ Downloaded from units or CFU for the frozen stock should be determined subsequently. On the day the assay is to be performed, the specimen should be thawed, diluted in fresh medium to yield 1,000 to 10,000 color-changing units or CFU/0.2 ml, and incubated (37°C) for 2 h prior to assay to allow the organism to begin active growth. A final color-changing unit count should be determined at this time. If results indicate that the number of organisms used in the assay falls outside the acceptable range of 1,000 to 10,000 per microtiter well, the assay must be considered invalid.
Mycoplasma reference strains for which the MICs of the antibiotics being tested are known should be routinely included for evaluation of the suitability of the antibiotic preparations being tested and to help control for any extraneous effects of pH or medium components. When a new drug is to be tested for antimycoplasmal activity, Staphylococcus aureus (ATCC 25923) and Enterococcus faecalis (ATCC 29212) or other appropriate bacterial reference strains should be tested according to guidelines from the National Committee for Clinical Laboratory Standards, using SP-4 and 10B broth, and results should be compared with results obtained using Mueller-Hinton broth to determine potential drug-mycoplasma medium interactions.
Each drug prepared according to guidelines from the National Committee for Clinical Laboratory Standards should be tested over a range of dilutions from 0.008 to 256 ,ug/ml. A drug control, positive organism control, and negative broth control should be included with each organism tested.
After inoculation, the microtiter plates should be sealed with acetate tape to prevent the release of ammonia contamination from a positive well to an adjacent negative well and also to prevent evaporation during long-term incubation.
Plates should be incubated at 37°C, and results should be determined as soon as the well containing the control organism is positive; for U. urealyticum, this could be as early as 16 h. The initial MIC is defined as the lowest dilution of antibiotic in which metabolism of the organism is inhibited as evidenced by lack of color change in the medium at the time the control organism well first shows color change. The final MIC is defined as the lowest dilution of antibiotic in which no further color change occurs at readings on two consecutive days after prolonged incubation.
To ensure reliable results, susceptibility testing should be performed in duplicate. Ideally, tests on those isolates found to be resistant should be repeated.
Therapy
Routine drug susceptibility testing of clinical isolates remains largely the province of a relatively small number of reference laboratories because of cost, time, and labor factors. This lack of diagnostic facilities in many areas coupled with the potentially serious nature of some of the systemic ureaplasmal infections in neonates makes empiric treatment necessary in many instances until proper microbiologic diagnosis and antimicrobial susceptibility information can be obtained.
Since ureaplasmas lack peptidoglycan, they are not affected by beta-lactam antibiotics. They are not susceptible to sulfonamides or trimethoprim because they do not synthesize folic acid. However, they are generally susceptible to certain antibiotics that interfere with protein synthesis, such as tetracyclines and macrolides, but usually not to lincosamides except in high concentrations. Some (145) . Data 2 ,ug/ml for doxycycline, 8 ,ug/ml for chloramphenicol, 8 ,g/ml for ciprofloxacin, 16 ,g/ml for clindamycin, and 32 ,ug/ml for gentamicin.
Among 
